Daniel P. Petrylak, MD, presented “ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers” for the Grand Rounds in Urology audience in October 2019.
How to cite: Petrylak, Daniel P. “ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers” December, 2019. Accessed Nov 2024. https://grandroundsinurology.com/esmo-astellas-seattle-genetics-keytruda-combo-shrinks-71-of-bladder-cancers/
ESMO: Astellas, Seattle Genetics’ Keytruda Combo Shrinks 71% of Bladder Cancers – Summary:
E. David Crawford, MD, interviews Daniel P. Petrylak, MD, about a Phase 1b trial of cisplatin-ineligible bladder cancer patients given a combination of pembrolizumab and enfortumab vedotin that resulted in a 71% response rate. Dr. Petrylak details what makes a patient cisplatin-ineligible, discusses the partial and complete responses to the drug combination, and lays out future plans to study the efficacy of this therapy in the treatment of urothelial cancer.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
